Reported about 2 months ago
Emergent BioSolutions Inc. has experienced a significant surge in stock value as investors await the FDA's decision regarding the use of its smallpox vaccine for the emerging mpox virus. Over recent sessions, the stock has risen more than 60%, influenced by the WHO declaring the mpox outbreak a global emergency. Other companies involved in vaccine development have also seen their stocks rise amid increased interest, despite challenges related to low demand for mpox vaccines in wealthier countries.
Source: YAHOO